MarketMoodz
11,460 Bottles of Chlorthalidone Recalled Over Dissolution Defect
Inventia Healthcare and U.S. distributor Rising Pharma Holdings have initiated a voluntary recall of 11,460 bottles of 25 mg chlorthalidone tablets after quality testing found the drug failed dissolution specifications. The recall covers 100- and 1,000-count bottles expiring April 2027 and is listed on the FDA recall page; investors should watch for costs, regulatory follow-up, and any expansion of the action.
Key Takeaways
- Voluntary recall covers 11,460 bottles of 25 mg chlorthalidone tablets sold in 100- and 1,000-count bottles.
- Affected batch codes are RISA24001 (100-count) and RISB24002 (1,000-count) with an April 2027 expiration date.
- Reason for recall: failed dissolution specifications detected during quality testing, which can affect drug release and efficacy.
- Recall was initiated on June 5 and is ongoing; the year of initiation is not specified in the notice and should be confirmed on the FDA page.
- Products were distributed in the United States; the FDA recall page and distributor notice are primary sources for updates.
People Involved
- No specific individuals mentioned
Entities Involved
- Inventia Healthcare LimitedManufacturer of the recalled chlorthalidone tablets (India)
- Rising Pharma HoldingsDistributor based in East Brunswick, NJ
- U.S. Food and Drug Administration (FDA)Regulatory authority listing the recall and overseeing safety/communications
- Fox BusinessSecondary news outlet reporting the recall
MarketMoodz Analysis
For investors, the immediate financial impact of this recall is likely to be limited by scale: 11,460 bottles is modest relative to large commercial drug volumes. Still, recalls tied to dissolution failures carry outsized reputational and regulatory risk. Expect direct costs for product retrieval and destruction, administrative and shipping expenses for the distributor, and possible remediation costs for the manufacturer if the issue traces to a production or formulation problem.
This action sits within a broader pattern of heightened FDA scrutiny of overseas manufacturing and batch-level quality control. Dissolution failures can trigger FDA follow-ups such as additional testing, inspections, Form 483 observations, or warning letters—each of which can disrupt supply and prompt longer-term corrective action plans. Investors should monitor the FDA recall page, any updates from Rising Pharma or Inventia, and whether the recall widens to other lots or products.
What to watch next: confirmation of the recall year and any FDA inspection outcomes; announcements about root-cause analysis, remediation steps, or liability exposure; and inventory or revenue guidance updates from the distributor or manufacturer. Clinicians, pharmacies, and patients should verify batch numbers (RISA24001 and RISB24002) against their supplies and follow FDA instructions for returns or disposal.
Source: Original Article